A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience
A Modified NHL-BFM-95 Regimen Produces Better Outcome Than HyperCVAD in Adult Patients with T-Lymphoblastic Lymphoma, a Two-Institution Experience
复制标题
两家机构的经验表明，改良的 NHL-BFM-95 方案在成年 T 淋巴细胞淋巴瘤患者中比 HyperCVAD 产生更好的结果
DOI：
10.4143/crt.2019.542
复制
发表时间：
2020-04-01
影响因子：
4.6
通讯作者：
Wang, Hua
中科院分区：
文献类型：
--
作者：
Li, Chun;Wuxiao, Zhi-Jun;Wang, Hua
淋巴母细胞性淋巴瘤（LBL）是一种前体T细胞或B细胞系的侵袭性肿瘤。一个广泛接受的标准治疗成人LBL尚未被defined.Materials和MethodsTo解决这个问题，我们比较了两个化疗方案：一个修改后的非霍奇金淋巴瘤柏林-法兰克福-明斯特-95（NHL-BFM-95）方案和HyperCVAD/MA。这项回顾性研究从2000年至2018年在两家医院连续招募了207名成人LBL患者。单因素和多因素分析被用来评估预后factors.ResultsIn本研究中，大多数临床特征是相似的两个治疗组之间的年龄和乳酸脱氢酶（LDH）水平除外。改良NHL-BFM-95方案治疗的患者倾向于年轻和LDH水平升高。在T-LBL患者或< 40岁患者中，改良NHL-BFM-95方案的治疗结局优于HyperCVAD/MA方案。HyperCVAD/MA治疗、东部肿瘤协作组评分高和骨髓受累是T-LBL的独立风险因素。无一例因严重不良事件而中断治疗。结论改良方案对T-LBL或< 40岁患者耐受性好，疗效满意。
PurposeLymphoblastic lymphoma (LBL) is an invasive neoplasm of precursor T-cell or B-cell lineage. A broadly accepted standard treatment for adult LBL has not yet been defined.Materials and MethodsTo address this issue, we compared two chemotherapy regimens: a modified non-Hodgkin lymphoma Berlin-Frankfurt-Munster-95 (NHL-BFM-95) regimen and HyperCVAD/MA. This retrospective study consecutively enrolled 207 adult LBL patients at two hospitals from 2000 to 2018. Univariate and multivariate analysis were used to assess prognostic factors.ResultsIn the present study, most clinical characteristics were similar between the two treatment groups except for age and lactate dehydrogenase (LDH) level. Patients treated with modified NHL-BFM-95 regimen tended to be younger and with elevated LDH level. The modified NHL-BFM-95 regimen produced better treatment outcomes than those with HyperCVAD/MA in patients with T-LBL or patients < 40 years. Treatment with HyperCVAD/MA, high Eastern Cooperative Oncology Group scores, and bone marrow involvement were independent risk factors in T-LBL. No patients interrupted treatment for severe adverse events.ConclusionThe results suggested that the modified regimen is well-tolerated and can produce the promising outcomes in patients with T-LBL or patients < 40 years.